Skip to main content
SpringerLink
Log in

Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstracts

Antithrombin is expected to modulate both prothrombotic and proinflammatory reactions in sepsis; vascular endothelium is the primary target. In the present study, we sought to evaluate the protective effects of a newly developed fucose-deficient recombinant antithrombin. Endothelial cells were treated in vitro with histone H4 to induce cellular damage. Low to high doses of either plasma-derived antithrombin or recombinant thrombomodulin were used as treatment interventions. Morphological change, apoptotic rate, cell viability, cell injury, and syndecan-4 level in the medium were evaluated. Immunofluorescent staining with anti-syndecan-4 was also performed. Both types of antithrombin reduced cellular damage and apoptotic cell death. Both plasma-derived and recombinant antithrombin improved cell viability and reduced cellular injury when administered at a physiological concentration or higher. Syndecan-4 staining became evident after treatment with histone H4, and both antithrombins suppressed the staining intensity at similar levels. The syndecan-4 level in the medium was significantly decreased by both antithrombins. None of the indicators showed a significant difference between plasma-derived and recombinant antithrombin. In conclusion, both recombinant and plasma-derived antithrombin can protect vascular endothelial cells. Recombinant antithrombin may represent a useful new therapeutic agent for sepsis-associated vascular damage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bucur SZ, Levy JH, Despotis GJ, Spiess BD, Hillyer CD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion. 1998;38:481–98.

    Article  CAS  PubMed  Google Scholar 

  2. Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, Pike RN. Antithrombin: in control of coagulation. Int J Biochem Cell Biol. 2004;36:386–9.

    Article  CAS  PubMed  Google Scholar 

  3. Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016;115:712–28.

    Article  PubMed  Google Scholar 

  4. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103:253–61.

    Article  CAS  PubMed  Google Scholar 

  5. Franzén LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. J Biol Chem. 1980;255:5090–3.

    PubMed  Google Scholar 

  6. Mizuochi T, Fujii J, Kurachi K, Kobata A. Structural studies of the carbohydrate moiety of human antithrombin III. Arch Biochem Biophys. 1980;203:458–65.

    Article  CAS  PubMed  Google Scholar 

  7. Brennan SO, George PM, Jordan RE. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. FEBS Lett. 1987;219:431–6.

    Article  CAS  PubMed  Google Scholar 

  8. Turk B, Brieditis I, Bock SC, Olson ST, Björk I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 1997;36:6682–91.

    Article  CAS  PubMed  Google Scholar 

  9. McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW. Structure of beta-antithrombin and the effect of glycosylation on antithrombin’s heparin affinity and activity. J Mol Biol. 2003;326:823–33.

    Article  CAS  PubMed  Google Scholar 

  10. Martínez-Martínez I, Navarro-Fernández J, Østergaard A, Gutiérrez-Gallego R, Padilla J, Bohdan N, et al. Amelioration of the severity of heparin binding antithrombin mutations by posttranslational mosaicism. Blood. 2012;120:900–4.

    Article  PubMed  Google Scholar 

  11. Fan B, Crews BC, Turko IV, Choay J, Zettlmeissl G, Gettins P. Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure. J Biol Chem. 1993;268:17588–96.

    CAS  PubMed  Google Scholar 

  12. Garone L, Edmunds T, Hanson E, Bernasconi R, Huntington JA, Meagher JL, et al. Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Biochemistry. 1996;35:8881–9.

    Article  CAS  PubMed  Google Scholar 

  13. Olson ST, Frances-Chmura AM, Swanson R, Björk I, Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. Arch Biochem Biophys. 1997;341:212–21.

    Article  CAS  PubMed  Google Scholar 

  14. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004;87:614–22.

    Article  CAS  PubMed  Google Scholar 

  15. Stanley P, Chaney W. Control of carbohydrate processing: the lec1A CHO mutation results in partial loss of N-acetylglucosaminyltransferase I activity. Mol Cell Biol. 1985;5:1204–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Yamada T, Kanda Y, Takayama M, Hashimoto A, Sugihara T, Satoh-Kubota A, et al. Comparison of biological activities of human antithrombins with high-mannose or complex-type nonfucosylated N-linked oligosaccharides. Glycobiology. 2016;26:482–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125:6–11.

    Article  CAS  PubMed  Google Scholar 

  18. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull. 1996;19:1518–20.

    Article  CAS  PubMed  Google Scholar 

  19. Hirose M, Kameyama S, Ohi H. Characterization of N-linked oligosaccharides attached to recombinant human antithrombin expressed in the yeast Pichia pastoris. Yeast. 2002;19:1191–202.

    Article  CAS  PubMed  Google Scholar 

  20. Schouten M, Wiersinga WJ, Levi M, van Der PT. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83:536–45.

    Article  CAS  PubMed  Google Scholar 

  21. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 2007;9:121–67.

    Article  CAS  PubMed  Google Scholar 

  22. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454:345–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Iwase M, Yoshikai Y, et al. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J Biol Chem. 2001;276:47483–8.

    Article  CAS  PubMed  Google Scholar 

  24. Chaaban H, Keshari RS, Silasi-Mansat R, Popescu NI, Mehta-D’Souza P, Lim YP, et al. Inter-α inhibitor protein and its associated glycosaminoglycans protect against histone-induced injury. Blood. 2015;125:2286–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chappell D, Jacob M, Hofmann-Kiefer K, Rehm M, Welsch U, Conzen P, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res. 2009;83:388–96.

    Article  CAS  PubMed  Google Scholar 

  26. Kaneider NC, Förster E, Mosheimer B, Sturn DH, Wiedermann CJ. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost. 2003;90:1150–7.

    CAS  PubMed  Google Scholar 

  27. Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc Res. 2010;87:300–10.

    Article  CAS  PubMed  Google Scholar 

  28. Longley RL, Woods A, Fleetwood A, Cowling GJ, Gallagher JT, Couchman JR. Control of morphology, cytoskeleton and migration by syndecan-4. J Cell Sci. 1999;112:3421–31.

    CAS  PubMed  Google Scholar 

  29. Woods A, Couchman JR. Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell. 1994;5:183–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Couchman JR. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol. 2010;26:89–114.

    Article  CAS  PubMed  Google Scholar 

  31. Iba T. Glycocalyx regulates the intravascular hemostasis. Juntendo Med J. 2016;62:444–9.

    Article  Google Scholar 

  32. De Jong MC, Walstra CM. Immunofluorescent localization of antithrombin III in human skin. Br J Dermatol. 1982;106:281–5.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the fund from Ministry of Education, Culture, Sports, Science and Technology-Supported Program for the Strategic Research Foundation at Private Universities 2016. All the authors have read and approved the final manuscript.

Author information

Authors and Affiliations

  1. Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo, 113-8421, Japan

    Toshiaki Iba

  2. Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Tatsuhiko Hirota

  3. Department of Surgery, Juntendo Shizuoka Hospital, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Koichi Sato

  4. Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Isao Nagaoka

Authors
  1. Toshiaki Iba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsuhiko Hirota
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koichi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isao Nagaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiaki Iba.

Ethics declarations

Conflict of interest

The authors have no competing interests to declare.

Electronic supplementary material

Below is the link to the electronic supplementary material.

12185_2018_2402_MOESM1_ESM.pptx

Supplement 1. Time-course and dose–response of cell viability after treatment with histone H4. Vascular endothelial cell viability was measured based on the CCK-8 level in the culture medium. Cell viability started to decrease 6 h after the treatment with histone H4, and the level decreased in a dose-dependent manner. Cell viability was decreased nearly half of the initial level when the dose was 50 μg/mL. Data are expressed as the mean ± standard error. CCK-8: cell counting kit-8 (PPTX 94 kb)

12185_2018_2402_MOESM2_ESM.ppt

Supplement 2. SDS-PAGE for various types of antithrombin. The cathode (-) is located at the top of the gel (pH4), while the anode (+) is at the bottom (pH6.5). Fifteen micrograms of protein was loaded in each lane of either 20% or 7.5% (w/v) acrylamide gel. Each protein band was stained with Coomassie Brilliant Blue. Both α- and β-antithrombin were recognized as blue bands located near 58 kDa. In contrast, AT-γ was recognized as wider bands. SDS-PAGE: Sodium dodecyl sulfate–polyacrylamide gel electrophoresis, α-AT: α-antithrombin, β-AT: β-antithrombin, Pd-AT: plasma-derived antithrombin, AT-γ: antithrombin-γ (PPT 589 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iba, T., Hirota, T., Sato, K. et al. Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage. Int J Hematol 107, 528–534 (2018). https://doi.org/10.1007/s12185-018-2402-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-018-2402-x

Keywords

Search

Navigation